Odomzo Approval History
Odomzo (sonidegib) is a hedgehog pathway inhibitor indicated for the treatment of locally advanced basal cell carcinoma (BCC).
Development History and FDA Approval Process for Odomzo
|Jul 24, 2015||FDA Approves Odomzo (sonidegib) for Locally Advanced Basal Cell Carcinoma|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.